UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
Tender Offer Statement under Section 14(d)(1)
or 13(e)(1)
of the Securities Exchange Act of 1934
AYTU
BIOPHARMA, INC.
(Name of Subject Company (issuer))
ROSEAPOLLO
MERGER SUB, Inc.
(Offeror)
A wholly-owned subsidiary of
Rosemont Pharmaceuticals Holdings, Inc.
(Parent of Offeror)
(Names of Filing Persons (identifying status
as offeror, issuer or other person))
Common stock, $0.0001 par value per share
(Title of Class of Securities)
054754858
(CUSIP Number of Class of Securities)
Kerry Sharp
General Counsel
Rosemont Pharmaceuticals Ltd.
Rosemont House, Yorkdale Industrial Park, Braithwaite
Street,
Leeds, LS11 9XE
Telephone: +44 (0)113 244 1400
(Name, address, and telephone numbers of person
authorized to receive notices and communications on behalf of filing persons)
Copy to:
Jackie Cohen; Janet Coscino
Ropes & Gray, LLP
1211 Avenue of the Americas
New York, New
York 10036
| x | Check the box if the filing relates solely to preliminary communications
made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to
which the statement relates:
| x | Third-party tender offer subject
to Rule 14d-1. |
| ¨ | Going-private transaction subject
to Rule 13e-3. |
| ¨ | Issuer tender offer subject to
Rule 13e-4. |
| ¨ | Amendment to Schedule 13D under
Rule 13d-2. |
Check the following box if the filing is a final amendment reporting
the results of the tender offer: ¨
If applicable, check the appropriate box(es) below to designate the
appropriate rule provision(s) relied upon:
| ¨ | Rule 13e-4(i) (Cross-Border Issuer
Tender Offer). |
| ¨ | Rule 14d-1(d) (Cross-Border Third-Party
Tender Offer). |
This Tender Offer Statement on Schedule TO relates
solely to preliminary communications made before the commencement of a planned tender offer by RoseApollo Merger Sub, Inc., a Delaware
corporation (“Purchaser”) and a wholly owned subsidiary of Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation
(“Parent”), for all of the outstanding shares of common stock of Aytu BioPharma, Inc., a Delaware corporation (the “Company”),
pursuant to the Agreement and Plan of Merger, dated as of November 16, 2026 (the “Merger Agreement”), among Parent, Purchaser
and the Company.
In connection with the proposed acquisition of
the Company, Parent will cause Purchaser to commence a tender offer for all of the outstanding shares of common stock of the Company.
The tender offer for all of the outstanding shares of the Company described in this filing has not yet commenced. This filing is for informational
purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor
is it a substitute for the tender offer materials that Parent and Purchaser will file with the SEC upon commencement of the tender offer.
A solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Rosemont
and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Parent and Purchaser will file
tender offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC
with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN
OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION
AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS
OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender
offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement,
will be made available to all stockholders of the Company at no expense to them on the SEC’s website at www.sec.gov and (once they
become available) will be mailed to the stockholders of the Company free of charge. Additional copies may be obtained for free by contacting
the Company, or by contacting Sodali & Co, the information agent for the Offer, toll-free at (800) 662-5200 or at AYTU.info@investor.sodali.com
The information contained in, or that can be accessed through, the SEC’s website is not a part of, or incorporated by reference
herein. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the
Solicitation/Recommendation Statement, the Company files annual, quarterly, and current reports, proxy statements and other information
with the SEC. You may read any reports, statements or other information filed by the Company with the SEC for free on the SEC’s
website at www.sec.gov.
Cautionary Statement Regarding Forward-Looking
Statements
This filing includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act
of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release
are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such
as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,”
“believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,”
or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are predictions
and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties
include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how
many stockholders of the Company will tender their shares in the tender offer; the possibility that the conditions to the tender offer
and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement;
the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder
litigation or regulatory action relating to the transaction; the Company’s overall financial and operational performance, potential
adverse changes to the Company’s financial position or its business, the results of operations, strategy and plans, changes in capital
markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its
products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges
and future events under current and potential future collaborations. Readers should refer to the risks described in “Risk Factors”
in Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and in the other reports and documents it files with
the United States Securities and Exchange Commission, as well as the tender offer documents to be filed by Rosemont and the Schedule 14D-9
to be filed by the Company.
Item 12. Exhibits
| |
|
|
| Exhibit No. |
|
Description |
| |
|
| Exhibit 99.1 |
|
Press Release issued on November 16, 2026 |